NASDAQ:LIFE

Atyr Pharma Stock Insider Trading

> Biotechnology

Buy LIFE

*Your capital is at risk

$16.89

-0.375 (-2.17%)

At Close: Jun 03, 2026

aTyr Pharma Stock Insider Power

Based on the 17 latest insides trades, we have calculated the insider power to be negative at -100.00. In total, the insiders bought 8.31M and sold 10.33M LIFE shares in the last 17 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 17 transactions)	-100.00
● Buy	8.31M shares
● Sell	10.33M shares
24% Buy Activity Strong Negative Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 15, 2026 Sell	Class A Common Stock J-Other	Gv 2019 Gp, L.l.c. 10 Percent Owner	10% Owner	87 475 Value: $0
May 15, 2026 Sell	Class A Common Stock S-Sale	Gv 2019 Gp, L.l.c. 10 Percent Owner	10% Owner	45 410 Value: $1.06M
May 15, 2026 Sell	Class A Common Stock S-Sale	Gv 2019 Gp, L.l.c. 10 Percent Owner	10% Owner	42 065 Value: $1.02M
May 14, 2026 Sell	Class A Common Stock J-Other	Gv 2019 Gp, L.l.c. 10 Percent Owner	10% Owner	60 077 Value: $0
May 14, 2026 Sell	Class A Common Stock S-Sale	Gv 2019 Gp, L.l.c. 10 Percent Owner	10% Owner	60 077 Value: $1.38M
Jan 30, 2026 Buy	Class A Common Stock C-Conversion	Softbank Group Corp. 10 Percent Owner	10% Owner	2 697 089 Value: $40.6M
Jan 30, 2026 Sell	Series A-2 Preferred Stock C-Conversion	Softbank Group Corp. 10 Percent Owner	10% Owner	11 830 Value: $0
Jan 30, 2026 Sell	Series A Preferred Stock C-Conversion	Softbank Group Corp. 10 Percent Owner	10% Owner	394 139 Value: $0
Jan 30, 2026 Sell	Series D-1 Preferred Stock C-Conversion	Softbank Group Corp. 10 Percent Owner	10% Owner	2 192 203 Value: $0
Jan 30, 2026 Buy	Class A Common Stock C-Conversion	Gv 2017 Gp, L.l.c. 10 Percent Owner	10% Owner	3 287 925 Value: $49.5M
Jan 30, 2026 Sell	Class A Common Stock S-Sale	Gv 2017 Gp, L.l.c. 10 Percent Owner	10% Owner	89 676 Value: $1.70M
Jan 30, 2026 Buy	Class A Common Stock C-Conversion	Gv 2017 Gp, L.l.c. 10 Percent Owner	10% Owner	1 755 632 Value: $26.4M
Jan 30, 2026 Buy	Class A Common Stock C-Conversion	Gv 2017 Gp, L.l.c. 10 Percent Owner	10% Owner	571 907 Value: $8.61M
Jan 30, 2026 Sell	Class A Common Stock S-Sale	Gv 2017 Gp, L.l.c. 10 Percent Owner	10% Owner	1 755 632 Value: $33.4M
Jan 30, 2026 Sell	Series B Preferred Stock C-Conversion	Gv 2017 Gp, L.l.c. 10 Percent Owner	10% Owner	1 751 791 Value: $0
Jan 30, 2026 Sell	Series C Preferred Stock C-Conversion	Gv 2017 Gp, L.l.c. 10 Percent Owner	10% Owner	3 287 925 Value: $0
Jan 30, 2026 Sell	Series D Preferred Stock C-Conversion	Gv 2017 Gp, L.l.c. 10 Percent Owner	10% Owner	552 126 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ATYR PHARMA INC

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and ...

Read Full Profile Here